Skip to content

Author

A. Mahipal

We have 3 of 454 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Utilization of Circulating Tumor DNA Testing in Biliary Tract Cancers

Background: Circulating tumor DNA is a promising biomarker for molecular residual disease and recurrence surveillance in biliary tract cancers. We evaluated the association between postoperative tumor-informed ctDNA and recurrence-free survival (RFS) and assessed the performance of initial and longitudinal ctDNA survei...

M. Sheu, N. Naleid, O. Pawar et al. · 0 citations
Review Open access Oct 2026

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.

BACKGROUND AIMS To evaluate safety and efficacy of FGFR1-3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements (FGFR2F), mutations (FGFR2M), or amplifications (FGFR2A), previously treated with chemotherapy. APPROACH RESULTS Open-label, non-contro...

M. Borad, Michele Droz Dit Busset, M. Javle et al. · 0 citations
Open access Aug 2026

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC, an unmet need after first-line immunotherapy.

Nguyen H. Tran, M. Palmer, Angela Ulrich et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.